More absorption means fewer retreatments and less scarring1-3*
ABSORICA LD™ provides greater absorption and therapeutic serum levels at a lower dose2,4*

Write DAW-1 for up to 2x more absorption in a fasted state. Superscript *

Compared to ABSORICA® (isotretinoin),
with a similar safety profile2,4

In a 2-year post-treatment study,
95% of patients
did not need to be retreated after one treatment cycle.1,4*

Phase IV trial analyzing efficacy of ABSORICA® (isotretinoin) based on per protocol population N=166; N=119 patients completed the post-treatment period

Micronization technology maximizes isotretinoin absorption in a low-dose formulation4,5

ABSORICA LD has unique dosage strengths that are not substitutable4

Does not need to be taken with a meal2,4

Most common adverse reactions (incidence ≥ 5%) are: dry lips, dry skin, back pain, dry eye, arthralgia, epistaxis, headache, nasopharyngitis, chapped lips, dermatitis, increased creatine kinase, cheilitis, musculoskeletal discomfort, upper respiratory tract infection, reduced visual acuity.

Please see full Important Safety Information.

ABSORICA LD™ 32 mg is bioequivalent to ABSORICA® (isotretinoin) 40 mg in a Fed state

Bioequivalence chart

ABSORICA LD daily dosage by body weight4

Dosing by weight chart

Due to its low-dose formulation, ABSORICA LD has a new dosing recommendation: 0.4 mg/kg/day to 0.8 mg/kg/day in two divided doses with or without meals for 15 to 20 weeks.4

Adult patients whose disease is very severe with scarring or is primarily manifested on the trunk may require dosage adjustments up to 1.6 mg/kg/day for ABSORICA LD in divided doses, as tolerated.4

ABSORICA LD™ dosing calculator

Enter your patient’s weight to reveal their total daily doses and divided doses of ABSORICA LD.

Start here
Choose total daily dosage (mg) (Check one)

For patients requiring 0.4 mg/kg/day
For patients requiring 0.4 mg/kg/day

DAW-1 for the ABSORICA LD Difference

Write “ABSORICA LD, Dispense as Written-1” or “ABSORICA LD, DAW-1” every time you prescribe to make sure your patients receive ABSORICA LD.

Due to its unique, micronized formulation, there are no generic substitutes available for ABSORICA LD. This means if you write DAW-1, your patients are more likely to receive the therapy you’ve chosen that is right for them.4-6